Center-Authored Papers

Filters: Author is Erba, Harry P  [Clear All Filters]
A
Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Nand S et al..  2016.  Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.. Leukemia research. Abstract
C
Chauncey TR, Gundacker H, Shadman M, List AF, Dakhil SR, Erba HP, Slovak ML, Chen I-M, Willman CL, Kopecky KJ et al..  2010.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia.. British journal of haematology. 148(1):48-58. Abstract
Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J et al..  2009.  Myeloid growth factors.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(1):64-83.
Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP et al..  2007.  Myeloid growth factors. Clinical practice guidelines in oncology.. Journal of the National Comprehensive Cancer Network : JNCCN. 5(2):188-202.
E
Erba HP, Othus M, Walter RB, Kirschbaum MH, Tallman MS, Larson RA, Slovak ML, Kopecky KJ, Gundacker HM, Appelbaum FR.  2013.  Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.. Leukemia research. Abstract
G
Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, Gatti GS, Erba HP, McCoy S, Press OW et al..  2003.  Health status and quality of life in patients with early-stage Hodgkin's disease treated on Southwest Oncology Group Study 9133.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 21(18):3512-9. Abstract
K
Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M et al..  2010.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(4):549-55. Abstract
M
Medeiros BC, Othus M, Fang M, Appelbaum FR, Erba HP.  2015.  Cytogenetic heterogeneity negatively impacts outcomes in patients with acute myeloid leukemia.. Haematologica. 100(3):331-5. Abstract
N
Nand S, Othus M, Godwin JE, Willman CL, Norwood TH, Howard DS, Coutre SE, Erba HP, Appelbaum FR.  2013.  A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.. Blood. 122(20):3432-3439. Abstract
O
O'Brien S, Berman E, Borghaei H, DeAngelo DJ, DeVetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO et al..  2009.  NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(9):984-1023.
O'Donnell MR, Appelbaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG et al..  2008.  Acute myeloid leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 6(10):962-93.
Othus M, Appelbaum FR, Petersdorf SH, Kopecky KJ, Slovak M, Nevill T, Brandwein J, Larson RA, Stiff PJ, Walter RB et al..  2015.  Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(3):559-64. Abstract
P
Petersdorf SH, Kopecky KJ, Slovak M, Willman C, Nevill T, Brandwein J, Larson RA, Erba HP, Stiff PJ, Stuart RK et al..  2013.  A phase III study of gemtuzumab ozogamicin during induction and post-consolidation therapy in younger patients with acute myeloid leukemia.. Blood. Abstract
Q
Qu X, Othus M, Davison J, Wu Y, Yan L, Meshinchi S, Ostronoff F, Estey EH, Radich JP, Erba HP et al..  2017.  Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.. Cancer. Abstract
S
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D et al..  2017.  Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. :JCO2015662510. Abstract
T
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
W
Walter RB, Othus M, Löwenberg B, Ossenkoppele GJ, Petersdorf SH, Pabst T, Vekemans M-C, Appelbaum FR, Erba HP, Estey EH.  2015.  Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory Acute Myeloid Leukemia: Analysis of 1,892 Patients from HOVON/SAKK and SWOG.. Haematologica. 100(10):e409-e411.